Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Pre-treatment biopsy PDX by clinical molecular subtype

From: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Clinical molecular subtype Total implanteda Any tumor growth Verified human breast tumor (%) pCR
no yes
ER-/HER2+ 20 6 5 (25.0) 4/8 1/12
ER+/HER2+ 14 5 4 (28.6) 3/11 1/3
LumA 9 0 0 (0.0) 0/9 0/0
LumB 30 6 2 (6.7) 0/27 2/3
LumUnk 1 0 0 (0.0) 0/1 0/0
Triple negative 39 21 20 (51.3) 9/17 11/22
Total 113 38 31 (27.4) 16/73 15/40
  1. Abbreviations: PDX patient-derived xenograft, pCR pathological complete response, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
  2. aAn additional seven tumors were implanted and had growth but were not available for pathological confirmation n